Advancing innovative solutions for severe rare diseases

Committed to improving outcomes for patients living with severe, progressive, and underserved rare diseases.

Learn More

A ground-breaking advancement

AMPK activators, significant therapeutic opportunities

Direct activation of AMPK, a key regulator of cellular metabolism, is emerging as a promising strategy for treating ADPKD by addressing the disease’s underlying metabolic abnormalities that drive cyst growth.
SCY-770 is a novel, highly selective, clinical stage direct AMPK activator under development as a new therapeutic approach for ADPKD.

Learn More

Fungerps: our anti-fungal platform addressing antimicrobial resistance

The fungerps are an innovative weapon against the global threat posed by raising rates of fungi with antimicrobial resistance.
SCY-247, our second generation fungerp, with enhanced pharmacological properties, is under development for the treatment and prevention of severe and often fatal fungal diseases.

Learn More

Our pipeline

Our work on meaningful scientific breakthroughs has the power to change lives.

Learn More

Latest news

  • 03/31/26

    SCYNEXIS Announces $40.0 Million Private Placement

    Read More >
  • 03/31/26

    SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Read More >
  • 03/04/26

    SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

    Read More >
  • 02/26/26

    SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

    Read More >
  • 01/28/26

    SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

    Read More >
  • 01/21/26

    SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

    Read More >
  • 12/22/25

    SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

    Read More >
  • 11/19/25

    SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

    Read More >
  • 11/17/25

    Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

    Read More >
  • 11/05/25

    SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Read More >

View All

Interested in learning more about our products, partnership opportunities and more?

Learn More

Make a Difference

Join Our Team

Our people are on a mission to advance innovative, highly differentiated therapies that target the biology of diseases and make a real difference in the lives of people around the world. Are you up for the challenge? Discover why you should join SCYNEXIS in the fight against severe rare diseases.

Learn More